AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone513-755-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$174.72 million
Profitability
Miscellaneous
Employees570
OptionableOptionable
AtriCure (NASDAQ:ATRC) Frequently Asked Questions
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Thursday, April, 26th. The medical device company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. The medical device company earned $46.99 million during the quarter, compared to the consensus estimate of $45.43 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 10.41%. The business's revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.32) earnings per share. View AtriCure's Earnings History.
When is AtriCure's next earnings date?
What guidance has AtriCure issued on next quarter's earnings?
AtriCure issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220-228 million, compared to the consensus revenue estimate of $222.8 million.AtriCure also updated its FY 2018 guidance to EPS.
What price target have analysts set for ATRC?
5 brokers have issued twelve-month price targets for AtriCure's shares. Their predictions range from $30.00 to $40.00. On average, they expect AtriCure's share price to reach $35.75 in the next year. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Price Targets for AtriCure.
What is the consensus analysts' recommendation for AtriCure?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.
Has AtriCure been receiving favorable news coverage?
News articles about ATRC stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AtriCure earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include Insulet (PODD), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Nevro (NVRO), Atrion (ATRI) and Tactile Systems Technology (TCMD).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
- Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
- Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
- Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
- Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)
Who are AtriCure's major shareholders?
AtriCure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.98%), Hudson Executive Capital LP (3.45%), Millennium Management LLC (2.28%), Peregrine Capital Management LLC (1.76%), Tamarack Advisers LP (1.56%) and GW&K Investment Management LLC (1.34%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure.
Which institutional investors are selling AtriCure stock?
ATRC stock was sold by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, Quantum Capital Management, Assenagon Asset Management S.A., Public Employees Retirement System of Ohio, MUFG Securities EMEA plc, Bank of New York Mellon Corp, Emerald Advisers LLC and Barclays PLC. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky and Mark A Collar. View Insider Buying and Selling for AtriCure.
Which institutional investors are buying AtriCure stock?
ATRC stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Tamarack Advisers LP, BlackRock Inc., Millennium Management LLC, Sectoral Asset Management Inc, D. E. Shaw & Co. Inc., Bank of America Corp DE and Geode Capital Management LLC. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.
How do I buy shares of AtriCure?
Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
One share of ATRC stock can currently be purchased for approximately $33.19.
How big of a company is AtriCure?
AtriCure has a market capitalization of $1.28 billion and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.
What is AtriCure's official website?
How can I contact AtriCure?
AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.
MarketBeat Community Rating for AtriCure (NASDAQ ATRC)
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
